Efficacy of Simparica Trio® against induced infections of Ancylostoma braziliense and Ancylostoma ceylanicum in dogs

Table 1 Efficacy of a single dose of Simparica Trio® containing sarolaner, moxidectin and pyrantel pamoate against induced infections of larval (L₄), immature adult (L₅) and adult stages of Ancylostoma braziliense and the adult stage of A. ceylanicum in dogs

Study	Parasite—origin	Stage at time of treatment	Day of inoculation	Day of worm counts	Treatment group^a	N	Sex of dog	Mean age of dogs (weeks)^b	Mean body weight of dogs (kg)^c	Number of infected dogs	Total worm counts		Efficacy (%)	Efficacy compared to controls
Study	Parasite—origin	Stage at time of treatment	Day of inoculation	Day of worm counts	Treatment group^a	N	Sex of dog	Mean age of dogs (weeks)^b	Mean body weight of dogs (kg)^c	Number of infected dogs	Range (n)	AM (GM)	Efficacy (%)	P value	Test statistic
1	A. braziliense—RSA	L₄ larvae	− 7	8	Untreated	8	2F, 6M	9.8	3.46	8	134–211	173.1 (171.2)	–	–	–
1	A. braziliense—RSA	L₄ larvae	− 7	8	Simparica Trio®	8	4F, 4M	9.8	3.43	0	0–0	0.0 (0.0)	100	< 0.0001	t₍₃₎ = 90.72
2	A. braziliense—RSA	Immature adult (L₅)	− 11	8	Untreated	8	2F, 6M	12.0	3.55	8	115–198	163.6 (160.7)	–	–	–
2	A. braziliense—RSA	Immature adult (L₅)	− 11	8	Simparica Trio®	8	5F, 3M	12.0	3.39	0	0–0	0.0 (0.0)	100	< 0.0001	t₍₃₎ = 67.20
3	A. braziliense—RSA	Adult	− 27	7	Untreated	8	4F, 4M	14.6	7.40	8	215–380	295.8 (291.3)	–	–	–
3	A. braziliense—RSA	Adult	− 27	7	Simparica Trio®	8	4F, 4M	14.5	7.43	0	0–0	0.0 (0.0)	100	< 0.0001	t₍₃₎ = 83.07
4	A. ceylanicum—Thailand	Adult	− 21	7	Untreated	8	6F, 2M	15.0	6.65	8	60–271	139.0 (121.6)	–	–	–
4	A. ceylanicum—Thailand	Adult	− 21	7	Simparica Trio®	7	2F, 5M	15.0	6.70	0	0–0	0.0 (0.0)	100	0.0005	t₍₃₎ = 16.91

AM Arithmetic mean, F female, GM geometric mean, L4 fourth-stage larvae, L5 fifth-stage larvae, M male, N number of animals per group, RSA Republic of South Africa
^aSimparica trio® provided a minimum of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel
^bAge on day 0 when treatment was administered
^cBody weights were recorded on day - 1 (studies 1–3) or day 0 (study 4)

ISSN: 1756-3305